Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
MRNA · Nasdaq · Healthcare
Fundamental quality
30
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $18,471M | $12,202M | $13,336M | -$6,848M |
| 2022 | $19,263M | $8,362M | $4,581M | -$3,205M |
| 2023 | $6,848M | -$4,714M | -$3,825M | -$2,907M |
| 2024 | $3,236M | -$3,561M | -$4,055M | -$1,927M |
| 2025 | $1,944M | -$2,822M | -$2,065M | -$2,005M |
Between 2021 and 2025, revenue went from $18,471M to $1,944M (-89%) and net income went from $12,202M to -$2,822M (-123%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Moderna, Inc. a profitable company?
Over the last twelve months, no: Moderna, Inc. posts a negative net margin (-143.6%).
Does Moderna, Inc. have a lot of debt?
Not particularly. Its net debt is 0.41 times its EBITDA, a low level.
Is Moderna, Inc. growing?
Its revenue has fallen 48.6% annualized in recent years.
Does Moderna, Inc. generate cash?
Over the last twelve months its free cash flow was negative.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Moderna, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →